## FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL							
DMB Number:	3235-0287						
Estimated average burden							
nours per respon	se 0.5						

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	es)														
Name and Address of Reporting Person * Haqq Christopher					2. Issuer Name and Ticker or Trading Symbol Atara Biotherapeutics, Inc. [ATRA]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner					
(Last) (First) (Middle) 611 GATEWAY BOULEVARD, SUITE 900					3. Date of Earliest Transaction (Month/Day/Year) 03/15/2017						X Officer (give title below) Other (specify below)  EVP, R&D & Chief Scientific Of					
(Street) SOUTH SAN FRANCISCO, CA 94080				4. If	4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting PersonForm filed by More than One Reporting Person					
(City	7)	(State)	(Zip)		Tal	ble I - Noi	ı-Deri	vative S	ecurities	Acquir	ed, Disp	osed of, or	Beneficially	Owned		
1.Title of Security (Instr. 3)			2. Transaction Date (Month/Day/Yea	Exec any	2A. Deemed Execution Date, if any (Month/Day/Year)	Code (Instr. 8)		4. Securities Acqu (A) or Disposed o (D) (Instr. 3, 4 and 5)		of l	Beneficia	cially Owned Following ed Transaction(s)			Beneficial Ownership	
						Code	V	Amoun	(A) or (D)	Price				or Indirect (I) (Instr. 4)	(Instr. 4)	
Common	Stock		03/15/2017			S(1)		6,000	D	\$ 19.6	386,855			D		
Common	Stock										17,312			I	See footnote (2)	
Common	Stock									2	2,688			I	See footnote (3)	
Reminder: indirectly.	Report on a	separate line fo	or each class of se	curities	s beneficially	owned dire	Pers	ons wh					nformation		EC 1474 (9- 02)	
			Table II -		ative Securit		ed, Di	isposed (	of, or Ben	neficiall	·		ntrol numb	er.		
Security	2. Conversion or Exercise Price of Derivative Security		Execution I	d Date, if	4. Transaction Code	5. Numbe	S		cisable on Date	7. Tit Amo Unde Secu	tle and unt of erlying rities r. 3 and	of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Ownersl Form of Derivati Security Direct (I or Indire	Ownersh (Instr. 4)	
					Code V	(A) (D)		e rcisable	Expiration Date	on Title	Amount or Number of Shares					
Repor	ting O	wners														
				Relationships												
Repo	rting Owne	r Name / Add	Direct	or 10%	10% Owner Officer					Ot	ther					
SUITE 90	EWAY BO	OULEVARE			E	VP, R&I	) & C	Chief Sc	ientific (	Of						

# Signatures

/s/ Tina Gullotta, Attorney-in-Fact for Christopher Haqq	03/16/2017		
**Signature of Reporting Person	Date		

### **Explanation of Responses:**

\* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Transaction pursuant to Rule 10b5-1 Plan adopted December 7, 2015.
- (2) The shares are held by the Chris Haqq 2014 GRAT, of which the Reporting Person is trustee.
- (3) The shares are held by The Havenside Trust, of which the Reporting Person is trustee.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.